Afleveringen
-
Tom and Brian finish discussing ESMO 2024 highlights. Even without a guest Tom still interrupts a lot.
-
Silke joins us to discuss ESMO 2024 highlights, then the birds start singing....
-
Zijn er afleveringen die ontbreken?
-
Fresh of the Presidential session address, Tom discusses his data with Petros commenting.
-
Uromigos Japan with Yuji, Hiroshi and Nobu is formed and discuss Hiroshi's ESMO data.
-
Arun Azad describes this randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC
-
Matt Galsky describes his ESMO 2024 abstract of disitimab vedotiin + pembrlizumab in bladder cancer
-
Silke Gillessen joins us to discuss her Presidential session from ESMO 2024
-
Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC
-
Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC
-
Katy Beckermann discusses the TiNivo-2 study presented at ESMO 2024.
-
Silke joins Brian and Tom to discuss upcoming data in prostate, bladder and kidney cancer in Barcelona at ESMO 2024
-
Nima Sharifi joins Brian and Tom to discuss mechanisms of resistance to hormone therapy in prostate cancer
-
Ira Mellman delves into the update of this classic paper and the components of an effective anti-tumor immune response.
-
María, Christina y Elena analizan los cambios recientes en las directrices de la ESMO en el cáncer de riñón, vejiga y próstata.
-
Naomi Haas joins Tom and Brian in New York City at the World GU Conference to discuss several RCC topics
-
Eric Jonasch, Co-Chair of the NCCN RCC Guidelines, gives insight into the process of guideline modification and discusses updates in adjuvant, front-line and refractory RCC
-
Jonathan Rosenberg and a surprise guest discuss comorbidities and treatment-related side effects.
-
David Braun divides immune therapies into four groups and describes how novel treatments and targets work. Tom and Brian are both excited and, at times, sceptical.
-
Escuche nuestro primer podcast sobre los aspectos más destacados de ASCO en cáncer de vejiga, riñón y próstata
-
Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden answer a range of relevant and sometimes irrelevant questions
- Laat meer zien